Martina Amanzio

List of Publications by Year
in descending order

66 papers	5,623 citations	147726 31 h-index	114418 63 g-index
68 all docs	68 docs citations	68 times ranked	3670 citing authors

#	Article	IF	Citations
1	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. Lancet Regional Health - Europe, The, 2022, 12, 100253.	3.0	46
2	How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?. Expert Review of Clinical Pharmacology, 2021, 14, 439-444.	1.3	12
3	Investigating Neuroimaging Correlates of Early Frailty in Patients With Behavioral Variant Frontotemporal Dementia: A MRI and FDG-PET Study. Frontiers in Aging Neuroscience, 2021, 13, 637796.	1.7	6
4	The Role of Neuropsychological Factors in Perceived Threat of SARS-CoV-2 in Healthy Ageing. International Journal of Environmental Research and Public Health, 2021, 18, 5847.	1.2	6
5	Lockdown Effects on Healthy Cognitive Aging During the COVID-19 Pandemic: A Longitudinal Study. Frontiers in Psychology, 2021, 12, 685180.	1.1	26
6	Editorial: Physical and Cognitive Frailty in the Elderly: An Interdisciplinary Approach. Frontiers in Psychology, 2021, 12, 698819.	1.1	2
7	HypothalamicâEPituitaryâEAdrenal Activity in Adverse Events Reporting After Placebo Administration. Clinical Pharmacology and Therapeutics, 2021, 110, 1349-1357.	2.3	4
8	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines, 2021, 9, 1179.	2.1	7
9	Are Sleep Problems Related to Psychological Distress in Healthy Aging during the COVID-19 Pandemic? A Review. International Journal of Environmental Research and Public Health, 2021, 18, 10676.	1.2	8
10	A Possible Association Between Executive Dysfunction and Frailty in Patients With Neurocognitive Disorders. Frontiers in Psychology, 2020, 11, 554307.	1.1	11
11	Reduced Self-Awareness Following a Combined Polar and Paramedian Bilateral Thalamic Infarction. A Possible Relationship With SARS-CoV-2 Risk of Contagion?. Frontiers in Psychology, 2020, 11, 570160.	1.1	3
12	How Do Nocebo Phenomena Provide a Theoretical Framework for the COVID-19 Pandemic?. Frontiers in Psychology, 2020, 11, 589884.	1.1	26
13	Executive Dysfunction and Reduced Self-Awareness in Patients With Neurological Disorders. A Mini-Review. Frontiers in Psychology, 2020, 11, 1697.	1.1	19
14	Editorial: Unawareness of Illness in Neurological Disorders: A Focussed Neurocognitive Approach Shedding Light on Neuropsychological Deficits and Neural Underpinnings Potential Association. Frontiers in Psychology, 2020, 11, 622576.	1.1	1
15	Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions. Frontiers in Pharmacology, 2020, 11, 100.	1.6	5
16	Nocebo effects and psychotropic drug action - an update. Expert Review of Clinical Pharmacology, 2020, 13, 75-77.	1.3	2
17	Pain Anticipation and Nocebo-Related Responses: A Descriptive Mini-Review of Functional Neuroimaging Studies in Normal Subjects and Precious Hints on Pain Processing in the Context of Neurodegenerative Disorders. Frontiers in Pharmacology, 2019, 10, 969.	1.6	7
18	A novel neurocognitive approach for placebo analgesia in neurocognitive disorders. Experimental Gerontology, 2019, 118, 106-116.	1.2	5

#	Article	IF	Citations
19	Are Patients With Schizophrenia Spectrum Disorders More Prone to Manifest Nocebo-Like-Effects? A Meta-Analysis of Adverse Events in Placebo Groups of Double-Blind Antipsychotic Trials. Frontiers in Pharmacology, 2019, 10, 502.	1.6	11
20	Role of the Cingulate Cortex in Dyskinesias-Reduced-Self-Awareness: An fMRI Study on Parkinsonâ€™s Disease Patients. Frontiers in Psychology, 2018, 9, 1765.	1.1	25
21	Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes. International Psychogeriatrics, 2018, 30, 1871-1881.	0.6	22
22	Corrigendum to â€œNeural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementiaâ€•[Exp. Gerontol. 83 (2016) 158â€“164]. Experimental Gerontology, 2017, 96, 164-165.	1.2	4
23	A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease. Parkinsonism and Related Disorders, 2017, 39, 58-63.	1.1	20
24	Neuropsychological Correlates of Pre-Frailty in Neurocognitive Disorders: A Possible Role for Metacognitive Dysfunction and Mood Changes. Frontiers in Medicine, 2017, 4, 199.	1.2	22
25	Conceptualizing Placebo as Active Component and Adjunct in Psychological Treatment. , 2016, , .		0
26	Nocebo and Pain. , 2016, , 117-131.		3
27	Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia. Experimental Gerontology, 2016, 83, 158-164.	1.2	19
28	Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders. Journal of Clinical Psychopharmacology, 2016, 36, 475-482.	0.7	14
29	Experimental pain processing in individuals with cognitive impairment. Pain, 2015, 156, 1396-1408.	2.0	85
30	Nocebo vs. Placebo: The Challenges of Trial Design in Analgesia Research. Clinical Pharmacology and Therapeutics, 2015, 97, 143-150.	2.3	44
31	Unawareness of bipolar disorder: the role of the cingulate cortex. Neurocase, 2015, 21, 438-447.	0.2	15
32	Pain anticipation: An activation likelihood estimation metaâ€analysis of brain imaging studies. Human Brain Mapping, 2015, 36, 1648-1661.	1.9	113
33	Nocebo effects and psychotropic drug action. Expert Review of Clinical Pharmacology, 2015, 8, 159-161.	1.3	12
34	Pain in Parkinson Patients. , 2015, , 209-219.		0
35	Unawareness of deficits in ischemic injury: Role of the cingulate cortex. Neurocase, 2014, 20, 540-555.	0.2	18
36	Self-unawareness of levodopa induced dyskinesias in patients with Parkinsonâ€™s disease. Brain and Cognition, 2014, 90, 135-141.	0.8	34

#	Article	IF	Citations
37	The magnitude of nocebo effects in pain: A meta-analysis. Pain, 2014, 155, 1426-1434.	2.0	154
38	Activation likelihood estimation metaâ€analysis of brain correlates of placebo analgesia in human experimental pain. Human Brain Mapping, 2013, 34, 738-752.	1.9	165
39	Mechanisms of the placebo response. Pulmonary Pharmacology and Therapeutics, 2013, 26, 520-523.	1.1	78
40	Impaired Awareness of Deficits in Alzheimer's Disease: The Role of Everyday Executive Dysfunction. Journal of the International Neuropsychological Society, 2013, 19, 63-72.	1.2	50
41	A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. International Psychogeriatrics, 2012, 24, 698-707.	0.6	22
42	Shared â€œCoreâ€•Areas between the Pain and Other Task-Related Networks. PLoS ONE, 2012, 7, e41929.	1.1	59
43	Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Medicine, 2011, 17, 1228-1230.	15.2	248
44	Unawareness of deficits in Alzheimerâ€™s disease: role of the cingulate cortex. Brain, 2011, 134, 1061-1076.	3.7	124
45	The placebo response: How words and rituals change the patient's brain. Patient Education and Counseling, 2011, 84, 413-419.	1.0	118
46	Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology, 2011, 213, 791-797.	1.5	57
47	Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?. Recent Patents on CNS Drug Discovery, 2011, 6, 41-47.	0.9	16
48	Impaired awareness of movement disorders in Parkinsonâ€™s disease. Brain and Cognition, 2010, 72, 337-346.	0.8	53
49	A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain, 2009, 146, 261-269.	2.0	199
50	Metaphor comprehension in Alzheimerâ€™s disease: Novelty matters. Brain and Language, 2008, 107, 1-10.	0.8	97
51	The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect. Journal of Neuroscience, 2006, 26, 12014-12022.	1.7	359
52	Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain, 2001, 90, 205-215.	2.0	357
53	Response expectancies in placebo analgesia and their clinical relevance. Pain, 2001, 93, 77-84.	2.0	360
54	Quantitative EEG Responses to Ischaemic Arm Stress in Migraine. Cephalalgia, 2001, 21, 224-229.	1.8	14

#	Article	IF	Citations
55	Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems. Journal of Neuroscience, 1999, 19, 484-494.	1.7	781
56	Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia. Journal of Neuroscience, 1999, 19, 3639-3648.	1.7	323
57	Inducing placebo respiratory depressant responses in humans via opioid receptors. European Journal of Neuroscience, 1999, 11, 625-631.	1.2	113
58	Neurophysiologic assessment of nerve impairment in posterolateral and muscle-sparing thoracotomy. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 841-847.	0.4	189
59	Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain, 1998, 74, 205-211.	2.0	123
60	The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain, 1998, 75, 313-319.	2.0	70
61	Control of Postoperative Pain by Transcutaneous Electrical Nerve Stimulation After Thoracic Operations. Annals of Thoracic Surgery, 1997, 63, 773-776.	0.7	148
62	Postoperative Pain and Superficial Abdominal Reflexes After Posterolateral Thoracotomy. Annals of Thoracic Surgery, 1997, 64, 207-210.	0.7	93
63	THE NEUROBIOLOGY OF PLACEBO ANALGESIA: FROM ENDOGENOUS OPIOIDS TO CHOLECYSTOKININ. Progress in Neurobiology, 1997, 52, 109-125.	2.8	214
64	Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain, 1997, 71, 135-140.	2.0	183
65	Potentiation of placebo analgesia by proglumide. Lancet, The, 1995, 346, 1231.	6.3	183
66	Nocebo-Prone Behavior Contributes to SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. SSRN Electronic Journal, 0, , .	0.4	1